Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$0.79 - $5.98 $722,254 - $5.47 Million
-914,246 Reduced 92.85%
70,400 $60,000
Q1 2022

May 16, 2022

BUY
$4.25 - $10.4 $231,484 - $566,456
54,467 Added 5.86%
984,646 $5.43 Million
Q4 2021

Feb 14, 2022

BUY
$9.68 - $17.74 $9 Million - $16.5 Million
930,179 New
930,179 $9 Million

Others Institutions Holding RUBY

About Rubius Therapeutics, Inc.


  • Ticker RUBY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,357,000
  • Description
  • Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...
More about RUBY
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.